AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01085292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
Study NCT02193308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine FDC
Study NCT02193308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02193308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study NCT04283591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
Study NCT04283591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation Programme
Description: They will continue to receive the conventional rehabilitation programme.
Study NCT04283591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Rehabilitation Programme
Description: They will continue to receive the conventional rehabilitation programme.
Study NCT03458689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left hemicolectomy, laparoscopic technique
Description: Left hemicolectomy, Laparoscopic technique
Study NCT03458689 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left hemicolectomy, laparoscopic technique
Description: Left hemicolectomy, Laparoscopic technique
Study NCT04219644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Breatheasy device
Study NCT02110264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Description: Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
Study NCT02110264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XR-NTX+PN
Description: In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
Study NCT02110264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Participants assigned to the ETAU group will receive drug education.
Study NCT05084092 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy (IORT)
Description: If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
Study NCT05084092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain surgery
Description: Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
Study NCT02207218 — intervention group
Intervention type: DRUG
Intervention: turoctocog alfa
Description: No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
Study NCT02409771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECIZON Presbyopic
Description: Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
Study NCT01793883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Laninamivir Octanoate
Study NCT01793883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mg Laninamivir Octanoate
Study NCT01793883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04087239 — intervention group
Intervention type: OTHER
Intervention: HIV
Study NCT02058992 — intervention group
Intervention type: DRUG
Intervention: Ramelteon
Description: Ramelteon 8 mg tablets
Study NCT01793883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02191813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seresis®
Study NCT02191813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03068767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT04112394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anesthetic injection
Description: A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
Study NCT04112394 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard perioperative and postoperative analgesia protocol.
Description: Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
Study NCT02724527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR
Study NCT02724527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo capsule
Study NCT00584454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q Fever Vaccine (NDBR 105
Description: Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
Study NCT00966472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + Rosuvastatin
Description: Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
Study NCT01342510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study NCT01342510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study NCT01342510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/Magnesium
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study NCT05694728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Description: For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
Study NCT05694728 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study NCT03080259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulant Diversion Prevention (SDP)
Description: provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
Study NCT00918021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: normal dosage of olanzapine (the same dosage as on hospital ward)
Study NCT00918021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01137942 — intervention group
Intervention type: DRUG
Intervention: clarithromycin, metronidazole, proton pump inhibitor
Description: appropriate dose of antibiotics and proton pump inhibitor
Study NCT05751239 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: All participants answered an online questionaire. Out of the 837 participants 641 were included
Study NCT03044405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fluid challenge
Description: Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
Study NCT03044405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Focused transthoracic echocardiography
Description: Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
Study NCT01454921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolution: Young Women Taking Charge and Growing Stronger
Description: The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75).
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75).
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
Study NCT03492255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
Study NCT04961034 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: kasai portoenterostomy
Description: surgical creation of stoma between porta hepatis and jejunal loop
Study NCT03866824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of Platelet Enhanced Plasma(PRP)
Description: intra-articular injection
Study NCT03866824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of corticosteroids
Description: intra-articular injection
Study NCT03866824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMI
Description: A CONTROL RMI at 1 year follow-up.
Study NCT03866824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RMI
Description: A CONTROL RMI at 1 year follow-up.
Study NCT03110497 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single application multi-fraction brachytherapy
Description: Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
Study NCT03578341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orally Colostrum
Description: Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
Study NCT03578341 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Orally Colostrum
Description: Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
Study NCT02853097 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo blood collection
Study NCT02853097 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03241485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: 5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
Study NCT03241485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline intrathecal given in the same manner as the intervention groups.
Study NCT01974414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: orally administered cedar honey
Study NCT03390049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 Laser Treatment
Description: After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
Study NCT03390049 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Treatment
Description: After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
Study NCT01144897 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Acetate scan
Description: PET Acetate scans will be done to detect prostate cancer lesions.
Study NCT01144897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon-11 labeled Acetate
Description: C-11 Acetate is a radiotracer used in PET scanning
Study NCT03470272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FB Professional LED Red light therapy
Description: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
Study NCT03470272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effects of Red Light LED Therapy on Body Contouring
Description: Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
Study NCT02503956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perforated Punctal plugs
Description: Perforated punctal plugs
Study NCT02503956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crawford tube insertion
Study NCT02503956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crawford lacrimal tube
Study NCT01287832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
Study NCT01287832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT03899246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eight Percent Topical Capsaicin
Description: See arm description
Study NCT05668702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crossover design
Description: The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
Study NCT04504994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion condition
Description: cyberball game: ex- versus over-inclusion condition
Study NCT01074944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: Oral Capsule in 50 mg or 100 mg dosages
Study NCT03513991 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infant formula
Study NCT03513991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Study NCT01122186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Cognitive Behavioral Skills Training
Description: The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
Study NCT01122186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Attention Control
Description: During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery.
Study NCT00052598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV
Study NCT00052598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00052598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00052598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT02562573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI4050